| Bid | 10.75 |
| Market Cap | 1.70B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.12 |
| PE Ratio (ttm) | -9.94 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 14.54 |
| Volume | 905,479 |
| Avg. Volume (20D) | 1,482,781 |
| Open | 11.34 |
| Previous Close | 11.27 |
| Day's Range | 11.10 - 11.44 |
| 52-Week Range | 3.50 - 16.74 |
| Beta | undefined |
About WVE
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the t...
Analyst Forecast
According to 10 analyst ratings, the average rating for WVE stock is "Buy." The 12-month stock price forecast is $22, which is an increase of 97.66% from the latest price.
Next Earnings Release
Analysts project revenue of $20.35M, reflecting a -29.96% YoY shrinking and earnings per share of -0.28, making a 86.67% increase YoY.
3 months ago · seekingalpha.com
Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 CatalystWave Life Sciences announced positive results from its phase 1b/2a RestorAAtion-2 study using WVE-006 for the treatment of alpha-1 antitrypsin deficiency patients. A single subcutaneous administration...
